HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1

Journal of Biological Chemistry

Volumn 289, Issue 30, 2014, Pages 20526-20542

  Morales, Javier F ^a   Morin, Trevor J ^a,b   Yu, Bin ^a   Tatsuno, Gwen P ^a   O'Rourke, Sara M ^a,c   Theolis Jr , Richard ^a   Mesa, Kathryn A ^a   Berman, Phillip W ^a  

^a University of California Santa Cruz   (United States)

^b Two Pore Guys Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; MONOCLONAL ANTIBODIES; POLYSACCHARIDES; VACCINES;

ANTIBODY RESPONSE; BINDING ACTIVITIES; ENVELOPE PROTEINS; GLYCOPEPTIDES; HIGH AFFINITY; HIV-1 INFECTIONS; MULTIPLE STRAINS; SHEET STRUCTURE;

SCAFFOLDS (BIOLOGY);

GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MANNOSE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL; GENETICS; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RABBIT;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; GLYCOSYLATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MANNOSE; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RABBITS;

EID: 84905375159     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.554089     Document Type: Article

References (98)

1. Fischinger, P. J., Robey, W. G., Koprowski, H., Gallo, R. C., and Bolognesi, D. P. (1985) Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). Cancer Res. 45, 4694s-4699s
2. Francis, D. P., and Petricciani, J. C. (1985) The prospects for and pathways toward a vaccine for AIDS. N. Engl. J. Med. 313, 1586-1590
3. Nature Publishing Group (1985) Where now with AIDS? Nature 313, 254
4. Johnston, M. I., and Fauci, A. S. (2007) An HIV vaccine-evolving concepts. N. Engl. J. Med. 356, 2073-2081
5. McMichael, A. J., and Phillips, R. E. (1997) Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 15, 271-296
6. Stamatatos, L., Morris, L., Burton, D. R., and Mascola, J. R. (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15, 866-870
7. Doria-Rose, N. A., Klein, R. M., Daniels, M. G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S. A., Wyatt, R. T., Korber, B. T., Mascola, J. R., and Connors, M. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 1631-1636
8. Walker, L. M., Simek, M. D., Priddy, F., Gach, J. S., Wagner, D., Zwick, M. B., Phogat, S. K., Poignard, P., and Burton, D. R. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6, e1001028
9. Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., Birungi, J., Pozniak, A., McPhee, D. A., Manigart, O., Karita, E., Inwoley, A., Jaoko, W., Dehovitz, J., Bekker, L. G., Pitisuttithum, P., Paris, R., Walker, L. M., Poignard, P., Wrin, T., Fast, P. E., Burton, D. R., and Koff, W. C. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348
10. Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X., Shaw, G. M., Connors, M., Wyatt, R. T., and Mascola, J. R. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13, 1032-1034
11. Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., and Stamatatos, L. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769
12. Kwong, P. D., Mascola, J. R., and Nabel, G. J. (2013) Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13, 693-701
13. Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., Scanlan, C. N., Schief, W. R., Silvestri, G., Streeck, H., Walker, B. D., Walker, L. M., Ward, A. B., Wilson, I. A., and Wyatt, R. (2012) A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407
14. Excler, J. L., Tomaras, G. D., and Russell, N. D. (2013) Novel directions in HIV-1 vaccines revealed from clinical trials. Curr. Opin. HIV AIDS 8, 421-431
15. McCoy, L. E., and Weiss, R. A. (2013) Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 210, 209-223
16. Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G., Anthony, R. M., Zebroski, H., Hurley, A., Phogat, A., Chakrabarti, B., Li, Y., Connors, M., Pereyra, F., Walker, B. D., Wardemann, H., Ho, D., Wyatt, R. T., Mascola, J. R., Ravetch, J. V., and Nussenzweig, M. C. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640
17. Corti, D., Langedijk, J. P., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez-Rodriguez, B. M., Silacci, C., Pinna, D., Jarrossay, D., Balla-Jhagjhoorsingh, S., Willems, B., Zekveld, M. J., Dreja, H., O'Sullivan, E., Pade, C., Orkin, C., Jeffs, S. A., Montefiori, D. C., Davis, D., Weissenhorn, W., McKnight, A., Heeney, J. L., Sallusto, F., Sattentau, Q. J., Weiss, R. A., and Lanzavecchia, A. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5, e8805
18. Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J. P., Wang, S. K., Ramos, A., Chan-Hui, P. Y., Moyle, M., Mitcham, J. L., Hammond, P. W., Olsen, O. A., Phung, P., Fling, S., Wong, C. H., Phogat, S., Wrin, T., Simek, M. D., Protocol G Principal Investigators, Koff, W. C., Wilson, I. A., Burton, D. R., and Poignard, P. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470
19. Walker, L. M., Phogat, S. K., Chan-Hui, P. Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., Lehrman, J. K., Priddy, F. H., Olsen, O. A., Frey, S. M., Hammond, P. W., Protocol G Principal Investigators, Kaminsky, S., Zamb, T., Moyle, M., Koff, W. C., Poignard, P., and Burton, D. R. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289
20. Zhou, T., Georgiev, I., Wu, X., Yang, Z. Y., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., Yang, Y., Zhu, J., Nussenzweig, M. C., Sodroski, J., Shapiro, L., Nabel, G. J., Mascola, J. R., and Kwong, P. D. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817
21. Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., Longo, N. S., McKee, K., O'Dell, S., Louder, M. K., Wycuff, D. L., Feng, Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P. D., Roederer, M., Wyatt, R. T., Nabel, G. J., and Mascola, J. R. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861
22. Bonsignori, M., Hwang, K. K., Chen, X., Tsao, C. Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., Sinangil, F., Pancera, M., Yongping, Y., Zhang, B., Zhu, J., Kwong, P. D., O'Dell, S., Mascola, J. R., Wu, L., Nabel, G. J., Phogat, S., Seaman, M. S., Whitesides, J. F., Moody, M. A., Kelsoe, G., Yang, X., Sodroski, J., Shaw, G. M., Montefiori, D. C., Kepler, T. B., Tomaras, G. D., Alam, S. M., Liao, H. X., and Haynes, B. F. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998-10009
23. Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Bailer, R. T., Chakrabarti, B., Sharma, S. K., Alam, S. M., Wang, T., Yang, Y., Zhang, B., Migueles, S. A., Wyatt, R., Haynes, B. F., Kwong, P. D., Mascola, J. R., and Connors, M. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412
24. Mascola, J. R., and Haynes, B. F. (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225-244
25. McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J. P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O'Dell, S., Patel, N., Shahzadul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G. Y., Diwanji, D., Georgiev, I., Kwon, Y. D., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z. Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L. X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., and Kwong, P. D. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343
26. Pancera, M., Shahzad-Ul-Hussan, S., Doria-Rose, N. A., McLellan, J. S., Bailer, R. T., Dai, K., Loesgen, S., Louder, M. K., Staupe, R. P., Yang, Y., Zhang, B., Parks, R., Eudailey, J., Lloyd, K. E., Blinn, J., Alam, S. M., Haynes, B. F., Amin, M. N., Wang, L. X., Burton, D. R., Koff, W. C., Nabel, G. J., Mascola, J. R., Bewley, C. A., and Kwong, P. D. (2013) Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20, 804-813
27. Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P. S., Wang, S. K., Stanfield, R. L., Julien, J. P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C. H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., and Wilson, I. A. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103
28. Kong, L., Lee, J. H., Doores, K. J., Murin, C. D., Julien, J. P., McBride, R., Liu, Y., Marozsan, A., Cupo, A., Klasse, P. J., Hoffenberg, S., Caulfield, M., King, C. R., Hua, Y., Le, K. M., Khayat, R., Deller, M. C., Clayton, T., Tien, H., Feizi, T., Sanders, R. W., Paulson, J. C., Moore, J. P., Stanfield, R. L., Burton, D. R., Ward, A. B., and Wilson, I. A. (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796-803
29. Julien, J. P., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., Klasse, P. J., Burton, D. R., Sanders, R. W., Moore, J. P., Ward, A. B., and Wilson, I. A. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-1483
30. Julien, J. P., Lee, J. H., Cupo, A., Murin, C. D., Derking, R., Hoffenberg, S., Caulfield, M. J., King, C. R., Marozsan, A. J., Klasse, P. J., Sanders, R. W., Moore, J. P., Wilson, I. A., and Ward, A. B. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. U. S. A. 110, 4351-4356
31. Lyumkis, D., Julien, J. P., de Val, N., Cupo, A., Potter, C. S., Klasse, P. J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B., Wilson, I. A., and Ward, A. B. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484-1490
32. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Francis, D. P., Stablein, D., Birx, D. L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M. L., Michael, N. L., Kunasol, P., and Kim, J. H. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220
33. Nakamura, G. R., Fonseca, D. P., O'Rourke, S. M., Vollrath, A. L., and Berman, P. W. (2012) Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding. PLoS One 7, e39045
34. Montefiori, D. C., Karnasuta, C., Huang, Y., Ahmed, H., Gilbert, P., de Souza, M. S., McLinden, R., Tovanabutra, S., Laurence-Chenine, A., Sanders-Buell, E., Moody, M. A., Bonsignori, M., Ochsenbauer, C., Kappes, J., Tang, H., Greene, K., Gao, H., LaBranche, C. C., Andrews, C., Polonis, V. R., Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Self, S. G., Berman, P. W., Francis, D., Sinangil, F., Lee, C., Tartaglia, J., Robb, M. L., Haynes, B. F., Michael, N. L., and Kim, J. H. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431-441
35. Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., Liao, H. X., DeVico, A. L., Lewis, G. K., Williams, C., Pinter, A., Fong, Y., Janes, H., DeCamp, A., Huang, Y., Rao, M., Billings, E., Karasavvas, N., Robb, M. L., Ngauy, V., de Souza, M. S., Paris, R., Ferrari, G., Bailer, R. T., Soderberg, K. A., Andrews, C., Berman, P. W., Frahm, N., De Rosa, S. C., Alpert, M. D., Yates, N. L., Shen, X., Koup, R. A., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Rerks-Ngarm, S., Michael, N. L., and Kim, J. H. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286
36. Zolla-Pazner, S., deCamp, A. C., Cardozo, T., Karasavvas, N., Gottardo, R., Williams, C., Morris, D. E., Tomaras, G., Rao, M., Billings, E., Berman, P., Shen, X., Andrews, C., O'Connell, R. J., Ngauy, V., Nitayaphan, S., de Souza, M., Korber, B., Koup, R., Bailer, R. T., Mascola, J. R., Pinter, A., Montefiori, D., Haynes, B. F., Robb, M. L., Rerks-Ngarm, S., Michael, N. L., Gilbert, P. B., and Kim, J. H. (2013) Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 8, e53629
37. Karasavvas, N., Billings, E., Rao, M., Williams, C., Zolla-Pazner, S., Bailer, R. T., Koup, R. A., Madnote, S., Arworn, D., Shen, X., Tomaras, G. D., Currier, J. R., Jiang, M., Magaret, C., Andrews, C., Gottardo, R., Gilbert, P., Cardozo, T. J., Rerks-Ngarm, S., Nitayaphan, S., Pitisuttithum, P., Kaewkungwal, J., Paris, R., Greene, K., Gao, H., Gurunathan, S., Tartaglia, J., Sinangil, F., Korber, B. T., Montefiori, D. C., Mascola, J. R., Robb, M. L., Haynes, B. F., Ngauy, V., Michael, N. L., Kim, J. H., de Souza, M. S., and MOPH TAVEG Collaboration (2012) The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 28, 1444-1457
38. Rolland, M., Edlefsen, P. T., Larsen, B. B., Tovanabutra, S., Sanders-Buell, E., Hertz, T., deCamp, A. C., Carrico, C., Menis, S., Magaret, C. A., Ahmed, H., Juraska, M., Chen, L., Konopa, P., Nariya, S., Stoddard, J. N., Wong, K., Zhao, H., Deng, W., Maust, B. S., Bose, M., Howell, S., Bates, A., Lazzaro, M., O'Sullivan, A., Lei, E., Bradfield, A., Ibitamuno, G., Assawadarachai, V., O'Connell, R. J., deSouza, M. S., Nitayaphan, S., Rerks-Ngarm, S., Robb, M. L., McLellan, J. S., Georgiev, I., Kwong, P. D., Carlson, J. M., Michael, N. L., Schief, W. R., Gilbert, P. B., Mullins, J. I., and Kim, J. H. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417-420
39. Berman, P. W., Gray, A. M., Wrin, T., Vennari, J. C., Eastman, D. J., Nakamura, G. R., Francis, D. P., Gorse, G., and Schwartz, D. H. (1997) Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J. Infect. Dis. 176, 384-397
40. Gilbert, P. B., Self, S. G., and Ashby, M. A. (1998) Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics 54, 799-814
41. Gilbert, P. B., Peterson, M. L., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., Heyward, W. L., Jobes, D. V., Popovic, V., Self, S. G., Sinangil, F., Burke, D., and Berman, P. W. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191, 666-677
42. Berman, P. W. (1998) Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res. Hum. Retroviruses 14, S277-S289
43. Karnasuta, C., Paris, R. M., Cox, J. H., Nitayaphan, S., Pitisuttithum, P., Thongcharoen, P., Brown, A. E., Gurunathan, S., Tartaglia, J., Heyward, W. L., McNeil, J. G., Birx, D. L., de Souza, M. S., and Thai AIDS Vaccine Evaluation Group, Thailand (2005) Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23, 2522-2529
44. Forthal, D. N., Gilbert, P. B., Landucci, G., and Phan, T. (2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178, 6596-6603
45. Forthal, D. N., and Moog, C. (2009) Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4, 388-393
46. Berman, P. W., Huang, W., Riddle, L., Gray, A. M., Wrin, T., Vennari, J., Johnson, A., Klaussen, M., Prashad, H., Köhne, C., deWit, C., and Gregory, T. J. (1999) Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 265, 1-9
47. Yu, B., Morales, J. F., O'Rourke, S. M., Tatsuno, G. P., and Berman, P. W. (2012) Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. PLoS One 7, e43903
48. Andersson, K. M., and Stover, J. (2011) The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Vaccine 29, 6092-6099
49. Long, E. F., and Owens, D. K. (2011) The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine 29, 6113-6124
50. Lasky, L. A., Groopman, J. E., Fennie, C. W., Benz, P. M., Capon, D. J., Dowbenko, D. J., Nakamura, G. R., Nunes, W. M., Renz, M. E., and Berman, P. W. (1986) Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233, 209-212
51. Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K., and Eichberg, J. W. (1990) Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625
52. Nakamura, G. R., Byrn, R., Wilkes, D. M., Fox, J. A., Hobbs, M. R., Hastings, R., Wessling, H. C., Norcross, M. A., Fendly, B. M., and Berman, P. W. (1993) Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J. Virol. 67, 6179-6191
53. Haas, J., Park, E. C., and Seed, B. (1996) Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6, 315-324
54. Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, H., Lloyd, K. E., Bowman, C., Sutherland, L., Jeffries, T. L., Jr., Kozink, D. M., Stewart, S., Anasti, K., Jaeger, F. H., Parks, R., Yates, N. L., Overman, R. G., Sinangil, F., Berman, P. W., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Karasavva, N., Rerks-Ngarm, S., Kim, J. H., Michael, N. L., Zolla-Pazner, S., Santra, S., Letvin, N. L., Harrison, S. C., and Haynes, B. F. (2013) Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J. Virol. 87, 1554-1568
55. Wurm, F. M. (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22, 1393-1398
56. Morikawa, Y., Overton, H. A., Moore, J. P., Wilkinson, A. J., Brady, R. L., Lewis, S. J., and Jones, I. M. (1990) Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. AIDS Res. Hum. Retroviruses 6, 765-773
57. Wang, Y. H., Davies, A. H., and Jones, I. M. (1995) Expression and purification of glutathione S-transferase-tagged HIV-1 gp120: no evidence of an interaction with CD26. Virology 208, 142-146
58. Montefiori, D. C. (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 2005 Jan; Chapter 12: Unit 12.11
59. Beddows, S., Zheng, N. N., Herrera, C., Michael, E., Barnes, K., Moore, J. P., Daniels, R. S., and Weber, J. N. (2005) Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. Virology 337, 136-148
60. Gorny, M. K., Stamatatos, L., Volsky, B., Revesz, K., Williams, C., Wang, X. H., Cohen, S., Staudinger, R., and Zolla-Pazner, S. (2005) Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79, 5232-5237
61. Nitayaphan, S., Pitisuttithum, P., Karnasuta, C., Eamsila, C., de Souza, M., Morgan, P., Polonis, V., Benenson, M., VanCott, T., Ratto-Kim, S., Kim, J., Thapinta, D., Garner, R., Bussaratid, V., Singharaj, P., el-Habib, R., Gurunathan, S., Heyward, W., Birx, D., McNeil, J., Brown, A. E., and Thai AIDS Vaccine Evaluation Group (2004) Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190, 702-706
62. O'Rourke, S. M., Schweighardt, B., Scott, W. G., Wrin, T., Fonseca, D. P., Sinangil, F., and Berman, P. W. (2009) Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J. Virol. 83, 7728-7738
63. Davenport, T. M., Friend, D., Ellingson, K., Xu, H., Caldwell, Z., Sellhorn, G., Kraft, Z., Strong, R. K., and Stamatatos, L. (2011) Binding interactions between soluble HIV envelope glycoproteins and quaternary- structurespecific monoclonal antibodies PG9 and PG16. J. Virol. 85, 7095-7107
64. Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S., and Haynes, B. F. (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186
65. Sanders, R. W., Derking, R., Cupo, A., Julien, J. P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., Golabek, M., de Los Reyes, K., Ketas, T. J., van Gils, M. J., King, C. R., Wilson, I. A., Ward, A. B., Klasse, P. J., and Moore, J. P. (2013) A next-generation cleaved, soluble HIV-1 env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618
66. Haynes, B. F., and McElrath, M. J. (2013) Progress in HIV-1 vaccine development. Curr. Opin. HIV AIDS 8, 326-332
67. Gottardo, R., Bailer, R. T., Korber, B. T., Gnanakaran, S., Phillips, J., Shen, X., Tomaras, G. D., Turk, E., Imholte, G., Eckler, L., Wenschuh, H., Zerweck, J., Greene, K., Gao, H., Berman, P. W., Francis, D., Sinangil, F., Lee, C., Nitayaphan, S., Rerks-Ngarm, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Robb, M. L., Michael, N. L., Kim, J. H., Zolla-Pazner, S., Haynes, B. F., Mascola, J. R., Self, S., Gilbert, P., and Montefiori, D. C. (2013) Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 8, e75665
68. Gorny, M. K., Moore, J. P., Conley, A. J., Karwowska, S., Sodroski, J., Williams, C., Burda, S., Boots, L. J., and Zolla-Pazner, S. (1994) Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68, 8312-8320
69. Go, E. P., Hewawasam, G. S., Ma, B. J., Liao, H. X., Haynes, B. F., and Desaire, H. (2011) Methods development for analysis of partially deglycosylated proteins and application to an HIV envelope protein vaccine candidate. Int. J. Mass Spectrom. 305, 209-216
70. Kelly, S. M., Jess, T. J., and Price, N. C. (2005) How to study proteins by circular dichroism. Biochim. Biophys. Acta 1751, 119-139
71. Anderson, K. P., Lucas, C., Hanson, C. V., Londe, H. F., Izu, A., Gregory, T., Ammann, A., Berman, P. W., and Eichberg, J. W. (1989) Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J. Infect. Dis. 160, 960-969
72. Belshe, R. B., Graham, B. S., Keefer, M. C., Gorse, G. J., Wright, P., Dolin, R., Matthews, T., Weinhold, K., Bolognesi, D. P., and Sposto, R. (1994) Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 272, 475-480
73. Migasena, S., Suntharasamai, P., Pitisuttithum, P., Kitayaporn, D., Wasi, C., Huang, W., Vanichseni, S., Koompong, C., Kaewkungwal, J., Raktham, S., Ippolito, T., Hanson, C., Gregory, T., Heyward, W. L., Berman, P., and Francis, D. (2000) AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res. Hum. Retroviruses 16, 655-663
74. Evans, T. G., McElrath, M. J., Matthews, T., Montefiori, D., Weinhold, K., Wolff, M., Keefer, M. C., Kallas, E. G., Corey, L., Gorse, G. J., Belshe, R., Graham, B. S., Spearman, P. W., Schwartz, D., Mulligan, M. J., Goepfert, P., Fast, P., Berman, P., Powell, M., and Francis, D. (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19, 2080-2091
75. Doria-Rose, N. A., Georgiev, I., O'Dell, S., Chuang, G. Y., Staupe, R. P., McLellan, J. S., Gorman, J., Pancera, M., Bonsignori, M., Haynes, B. F., Burton, D. R., Koff, W. C., Kwong, P. D., and Mascola, J. R. (2012) A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J. Virol. 86, 8319-8323
76. Arthos, J., Cicala, C., Martinelli, E., Macleod, K., Van Ryk, D., Wei, D., Xiao, Z., Veenstra, T. D., Conrad, T. P., Lempicki, R. A., McLaughlin, S., Pascuccio, M., Gopaul, R., McNally, J., Cruz, C. C., Censoplano, N., Chung, E., Reitano, K. N., Kottilil, S., Goode, D. J., and Fauci, A. S. (2008) HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301-309
77. Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P., and Norcross, M. A. (1994) Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68, 6006-6013
78. Mascola, J. R., Snyder, S. W., Weislow, O. S., Belay, S. M., Belshe, R. B., Schwartz, D. H., Clements, M. L., Dolin, R., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Walker, M. C., Wagner, K. F., McNeil, J. G., McCutchan, F. E., and Burke, D. S. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173, 340-348
79. Beddows, S., Louisirirotchanakul, S., Cheingsong-Popov, R., Easterbrook, P. J., Simmonds, P., and Weber, J. (1998) Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J. Gen. Virol. 79, 77-82
80. Bonsignori, M., Montefiori, D. C., Wu, X., Chen, X., Hwang, K. K., Tsao, C. Y., Kozink, D. M., Parks, R. J., Tomaras, G. D., Crump, J. A., Kapiga, S. H., Sam, N. E., Kwong, P. D., Kepler, T. B., Liao, H. X., Mascola, J. R., and Haynes, B. F. (2012) Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86, 4688-4692
81. Pitisuttithum, P., Berman, P. W., Phonrat, B., Suntharasamai, P., Raktham, S., Srisuwanvilai, L. O., Hirunras, K., Kitayaporn, D., Kaewkangwal, J., Migasena, S., Sheppard, H. W., Li, E., Chernow, M., Peterson, M. L., Shibata, R., Heyward, W. L., and Francis, D. P. (2004) Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J. Acquir. Immune Defic. Syndr. 37, 1160-1165
82. Hoffenberg, S., Powell, R., Carpov, A., Wagner, D., Wilson, A., Kosakovsky Pond, S., Lindsay, R., Arendt, H., Destefano, J., Phogat, S., Poignard, P., Fling, S. P., Simek, M., Labranche, C., Montefiori, D., Wrin, T., Phung, P., Burton, D., Koff, W., King, C. R., Parks, C. L., and Caulfield, M. J. (2013) Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J. Virol. 87, 5372-5383
83. Alam, S. M., Dennison, S. M., Aussedat, B., Vohra, Y., Park, P. K., Fernández-Tejada, A., Stewart, S., Jaeger, F. H., Anasti, K., Blinn, J. H., Kepler, T. B., Bonsignori, M., Liao, H. X., Sodroski, J. G., Danishefsky, S. J., and Haynes, B. F. (2013) Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc. Natl. Acad. Sci. U. S. A. 110, 18214-18219
84. Amin, M. N., McLellan, J. S., Huang, W., Orwenyo, J., Burton, D. R., Koff, W. C., Kwong, P. D., and Wang, L. X. (2013) Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat. Chem. Biol. 9, 521-526
85. Bonomelli, C., Doores, K. J., Dunlop, D. C., Thaney, V., Dwek, R. A., Burton, D. R., Crispin, M., and Scanlan, C. N. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6, e23521
86. Doores, K. J., Bonomelli, C., Harvey, D. J., Vasiljevic, S., Dwek, R. A., Burton, D. R., Crispin, M., and Scanlan, C. N. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. U. S. A. 107, 13800-13805
87. Eggink, D., Melchers, M., Wuhrer, M., van Montfort, T., Dey, A. K., Naaijkens, B. A., David, K. B., Le Douce, V., Deelder, A. M., Kang, K., Olson, W. C., Berkhout, B., Hokke, C. H., Moore, J. P., and Sanders, R. W. (2010) Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401, 236-247
88. Pinter, A., Honnen, W. J., Kayman, S. C., Trochev, O., and Wu, Z. (1998) Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16, 1803-1811
89. Aussedat, B., Vohra, Y., Park, P. K., Fernández-Tejada, A., Alam, S. M., Dennison, S. M., Jaeger, F. H., Anasti, K., Stewart, S., Blinn, J. H., Liao, H. X., Sodroski, J. G., Haynes, B. F., and Danishefsky, S. J. (2013) Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J. Am. Chem. Soc. 135, 13113-13120
90. Bonsignori, M., Pollara, J., Moody, M. A., Alpert, M. D., Chen, X., Hwang, K. K., Gilbert, P. B., Huang, Y., Gurley, T. C., Kozink, D. M., Marshall, D. J., Whitesides, J. F., Tsao, C. Y., Kaewkungwal, J., Nitayaphan, S., Pitisuttithum, P., Rerks-Ngarm, S., Kim, J. H., Michael, N. L., Tomaras, G. D., Montefiori, D. C., Lewis, G. K., DeVico, A., Evans, D. T., Ferrari, G., Liao, H. X., and Haynes, B. F. (2012) Antibody-dependent cellular cytotoxicitymediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521-11532
91. Euler, Z., and Schuitemaker, H. (2012) Cross-reactive broadly neutralizing antibodies: timing is everything. Front. Immunol. 3, 215
92. Moore, P. L., Gray, E. S., Wibmer, C. K., Bhiman, J. N., Nonyane, M., Sheward, D. J., Hermanus, T., Bajimaya, S., Tumba, N. L., Abrahams, M. R., Lambson, B. E., Ranchobe, N., Ping, L., Ngandu, N., Abdool Karim, Q., Abdool Karim, S. S., Swanstrom, R. I., Seaman, M. S., Williamson, C., and Morris, L. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692
93. Yu, B., Fonseca, D. P., O'Rourke, S. M., and Berman, P. W. (2010) Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. J. Virol. 84, 1513-1526
94. Wu, L., Oficjalska, K., Lambert, M., Fennell, B. J., Darmanin-Sheehan, A., Ní Shúilleabháin, D., Autin, B., Cummins, E., Tchistiakova, L., Bloom, L., Paulsen, J., Gill, D., Cunningham, O., and Finlay, W. J. (2012) Fundamental characteristics of the immunoglobulin VH repertoire of chickens in comparison with those of humans, mice, and camelids. J. Immunol. 188, 322-333
95. Koff, W. C. (2012) HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 30, 4310-4315
96. Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W., and Choopanya, K. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671
97. Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N., and Gregory, T. J. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265, 10373-10382
98. Katoh, K., and Toh, H. (2008) Recent developments in the MAFFT multiple sequence alignment program. Brief. Bioinform. 9, 286-298